4-Tert-butylcyclohexanecarbonyl chloride → 1-Isopropyl-4-[5-(4-tert-butylcyclohexyl)[1,2,4]oxadiazol-3-yl]piperidine, Hydrochloride
Reaktionsgleichung
[CH:1]([N:4]1[CH2:9][CH2:8][CH:7]([C:10]([NH:12][OH:13])=[NH:11])[CH2:6][CH2:5]1)([CH3:3])[CH3:2].[C:14]([CH:18]1[CH2:23][CH2:22][CH:21]([C:24]([Cl:26])=O)[CH2:20][CH2:19]1)([CH3:17])([CH3:16])[CH3:15]>>[ClH:26].[CH:1]([N:4]1[CH2:9][CH2:8][CH:7]([C:10]2[N:11]=[C:24]([CH:21]3[CH2:22][CH2:23][CH:18]([C:14]([CH3:15])([CH3:17])[CH3:16])[CH2:19][CH2:20]3)[O:13][N:12]=2)[CH2:6][CH2:5]1)([CH3:3])[CH3:2]Komponenten
3
Versuchsvorschrift
The title compound was prepared by a similar procedure to that described in Example 56, starting from 1-isopropyl-N-hydroxypiperidine-4-carboxamidine and 4-tert-butylcyclohexanecarbonyl chloride.
Quellen und Nachweise
- ORD-Eintrag
- ord-d5e64d1c521745168382f604f85b75a9
- Quelldatensatz
- uspto-grants-2008_02